{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:41:10Z","timestamp":1793828470227,"version":"4.6.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.4065\/mcp.2009.0603","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T11:27:58Z","timestamp":1259753278000},"page":"1095-1110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":243,"title":["Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines"],"prefix":"10.4065","volume":"84","author":[{"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E. Detweiler","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.4065\/mcp.2009.0603_bib1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.4065\/mcp.2009.0603_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.4065\/mcp.2009.0603_bib4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/sj.leu.2403090","article-title":"Many and multiple myeloma(s)","volume":"17","author":"Fonseca","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0025-6196(11)61022-7","article-title":"Designing risk-adapted therapy for multiple myeloma: the Mayo perspective [editorial]","volume":"82","author":"Lonial","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0025-6196(11)61033-1","article-title":"Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis","volume":"82","author":"Markovic","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4065\/82.4.490","article-title":"Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment","volume":"82","author":"Markovic","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/mcp.2009.0603_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4065\/82.5.628","article-title":"Treatment options for hepatobiliary and pancreatic cancer","volume":"82","author":"Alberts","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0025-6196(11)61196-8","article-title":"Current management strategies for ovarian cancer","volume":"82","author":"Aletti","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.4065\/mcp.2009.0603_bib13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4065\/82.8.999","article-title":"A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis","volume":"82","author":"Pruthi","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/82.9.1131","article-title":"A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations","volume":"82","author":"Pruthi","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.4065\/mcp.2009.0603_bib15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4065\/82.10.1271","article-title":"Central nervous system tumors","volume":"82","author":"Buckner","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S0025-6196(11)61104-X","article-title":"Prevention, diagnosis, and treatment of cervical cancer","volume":"82","author":"Long","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.4065\/mcp.2009.0603_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4065\/83.1.97","article-title":"Current issues in the management of endometrial cancer","volume":"83","author":"Bakkum-Gamez","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4065\/83.3.355","article-title":"Small cell lung cancer","volume":"83","author":"Sher","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/mcp.2009.0603_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.4065\/mcp.2009.0603_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4065\/83.7.825","article-title":"Malignant melanoma in the 21st century: the emerging molecular landscape","volume":"83","author":"Sekulic","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.4065\/mcp.2009.0603_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan","volume":"82","author":"Iwanaga","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"10.4065\/mcp.2009.0603_bib25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"25","key":"10.4065\/mcp.2009.0603_bib26","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.4065\/mcp.2009.0603_bib28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1\u03b2-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/mcp.2009.0603_bib30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/1535-7163.MCT-06-0620","article-title":"Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach","volume":"6","author":"Fonseca","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.4065\/mcp.2009.0603_bib32","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.beha.2007.08.005","article-title":"Role of genetics in prognostication in myeloma","volume":"20","author":"Avet-Loiseau","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib35","first-page":"715","article-title":"Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (\u039413) in multiple myeloma: an Eastern Cooperative Oncology Group study","volume":"62","author":"Fonseca","year":"2002","journal-title":"Cancer Res"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0889-8588(05)70119-2","article-title":"Cytogenetic abnormalities in multiple myeloma","volume":"13","author":"Fonseca","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib37","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","article-title":"Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma","volume":"20","author":"Chiecchio","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib38","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib39","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum \u03b22-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.4065\/mcp.2009.0603_bib40","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib41","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","article-title":"Predictive role of interphase cytogenetics for survival of patients with multiple myeloma","volume":"18","author":"K\u00f6nigsberg","year":"2000","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.4065\/mcp.2009.0603_bib42","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.4065\/mcp.2009.0603_bib43","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"issue":"15","key":"10.4065\/mcp.2009.0603_bib44","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V55.3.364.364","article-title":"Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma","volume":"55","author":"Durie","year":"1980","journal-title":"Blood"},{"issue":"17","key":"10.4065\/mcp.2009.0603_bib46","first-page":"3854","article-title":"Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization","volume":"55","author":"Drach","year":"1995","journal-title":"Cancer Res"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib47","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.V91.9.3366","article-title":"Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes","volume":"91","author":"P\u00e9rez-Sim\u00f3n","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.4065\/mcp.2009.0603_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2141.1995.tb03387.x","article-title":"Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leon\u00e9s (Spain) Cooperative Group for the Study of Monoclonal Gammopathies","volume":"90","author":"Garc\u00eda-Sanz","year":"1995","journal-title":"Br J Haematol"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","article-title":"Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma","volume":"19","author":"Wuilleme","year":"2005","journal-title":"Leukemia"},{"issue":"26","key":"10.4065\/mcp.2009.0603_bib51","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib52","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.4065\/mcp.2009.0603_bib53","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.leu.2404172","article-title":"Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2141.1999.01615.x","article-title":"p53 deletion is not a frequent event in multiple myeloma","volume":"106","author":"Avet-Loiseau","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"10.4065\/mcp.2009.0603_bib56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib57","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labeling index and \u03b22-microglobulin predict survival indepen-dent of thymidine kinase and C-reactive protein in multiple myeloma","volume":"81","author":"Greipp","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.4065\/mcp.2009.0603_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.1999.01136.x","article-title":"Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders","volume":"104","author":"Witzig","year":"1999","journal-title":"Br J Haematol"},{"issue":"10","key":"10.4065\/mcp.2009.0603_bib59","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/83.10.1142","article-title":"Treatment of myeloma: cure vs control","volume":"83","author":"Rajkumar","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib60","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1704633","article-title":"Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.4065\/mcp.2009.0603_bib62","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"issue":"13","key":"10.4065\/mcp.2009.0603_bib63","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.4065\/mcp.2009.0603_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.4065\/mcp.2009.0603_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.11644","article-title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma","volume":"93","author":"Lokhorst","year":"2008","journal-title":"Haematologica"},{"issue":"11, pt 1","key":"10.4065\/mcp.2009.0603_bib67","first-page":"3593","article-title":"Thalidomide combinations improve response rates: results from the MRC IX Study [abstract 1051a]","volume":"110","author":"Morgan","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"10.4065\/mcp.2009.0603_bib68","first-page":"77","article-title":"Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract 77]","volume":"110","author":"Zonder","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.4065\/mcp.2009.0603_bib69","first-page":"74","article-title":"A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. [abstract]","volume":"110","author":"Rajkumar","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib70","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky","year":"2008","journal-title":"Blood"},{"key":"10.4065\/mcp.2009.0603_bib71","first-page":"91","article-title":"Phase II trial of lenalidomide (Revlimid\u2122) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. [abstract 91]","volume":"112","author":"Kumar","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"10.4065\/mcp.2009.0603_bib72","first-page":"450","article-title":"VELCADE\/Dexamethasone (Vel\/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005\/01 trial [abstract 450]","volume":"110","author":"Harousseau","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"pt 1","key":"10.4065\/mcp.2009.0603_bib73","first-page":"18S","article-title":"A phase II study of combination of bortezomib, liposomal doxorubin, and dexamethasone (VDD) as first line therapy for multiple myeloma [abstract 17504]","volume":"24","author":"Jakubowiak","year":"2006","journal-title":"J Clin Oncol. (ASCO Meeting Abstracts)"},{"issue":"11","key":"10.4065\/mcp.2009.0603_bib74","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00277-009-0726-6","article-title":"DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib\/dexamethasone for remission induction in patients with newly diagnosed myeloma","volume":"88","author":"Kropff","year":"2009","journal-title":"Ann Hematol"},{"issue":"7","key":"10.4065\/mcp.2009.0603_bib75","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.4065\/mcp.2009.0603_bib76","first-page":"30a","article-title":"Bortezomib (Velcade(R)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM) [abstract 73]","volume":"110","author":"Cavo","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.4065\/mcp.2009.0603_bib77","first-page":"92","article-title":"Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I\/II study. [abstract 92]","volume":"112","author":"Richardson","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.4065\/mcp.2009.0603_bib78","first-page":"93","article-title":"Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I\/II multi-center EVOLUTION study. [abstract 93]","volume":"112","author":"Kumar","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib79","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"issue":"28","key":"10.4065\/mcp.2009.0603_bib80","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics","volume":"25","author":"Rosi\u00f1ol","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib81","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib82","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"issue":"13","key":"10.4065\/mcp.2009.0603_bib83","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.4065\/mcp.2009.0603_bib84","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","article-title":"Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma","volume":"82","author":"Lacy","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib85","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10245330701214236","article-title":"Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma","volume":"12","author":"Wang","year":"2007","journal-title":"Hematology"},{"issue":"1","key":"10.4065\/mcp.2009.0603_bib86","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Jagannath","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib87","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib88","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2009-01-202010","article-title":"Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"114","author":"Kapoor","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.4065\/mcp.2009.0603_bib90","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/mcp.2009.0603_bib91","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","article-title":"Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib92","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"36","key":"10.4065\/mcp.2009.0603_bib93","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib94","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib95","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.4065\/mcp.2009.0603_bib96","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.4065\/mcp.2009.0603_bib97","first-page":"74","article-title":"A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]","volume":"110","author":"Rajkumar","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib98","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib99","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/sj.leu.2404661","article-title":"Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield","volume":"21","author":"Breitkreutz","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib100","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.4065\/mcp.2009.0603_bib101","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","article-title":"Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma","volume":"15","author":"Popat","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.4065\/mcp.2009.0603_bib102","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","article-title":"Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma","volume":"14","author":"Mark","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.4065\/mcp.2009.0603_bib103","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"10.4065\/mcp.2009.0603_bib104","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2009.0603_bib105","first-page":"2545","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 Trial [abstract 2545]","volume":"106","author":"Sonneveld","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"suppl 1","key":"10.4065\/mcp.2009.0603_bib106","first-page":"S59","volume":"4","author":"Fermand","year":"2003","journal-title":"Hematol J"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib107","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bj\u00f6rkstrand","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.4065\/mcp.2009.0603_bib108","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.4065\/mcp.2009.0603_bib109","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.4065\/mcp.2009.0603_bib110","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"23","key":"10.4065\/mcp.2009.0603_bib111","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","article-title":"Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling","volume":"13","author":"Haessler","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.4065\/mcp.2009.0603_bib112","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2006.06441.x","article-title":"Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease","volume":"136","author":"Pineda-Roman","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib113","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib114","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Haematol"},{"issue":"10","key":"10.4065\/mcp.2009.0603_bib115","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.4065\/mcp.2009.0603_bib116","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.4065\/mcp.2009.0603_bib117","first-page":"656","article-title":"Maintenance thalidomide may improve progression free but not overall survival: results from the Myeloma IX Maintenance Randomisation [abstract 656]","volume":"112","author":"Morgan","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.4065\/mcp.2009.0603_bib118","first-page":"653","article-title":"First analysis of HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) Vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). [abstract 635]","volume":"112","author":"Sonneveld","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib119","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9513","key":"10.4065\/mcp.2009.0603_bib120","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.4065\/mcp.2009.0603_bib121","doi-asserted-by":"crossref","first-page":"63a","DOI":"10.1182\/blood.V104.11.206.206","volume":"104","author":"Facon","year":"2004","journal-title":"Blood"},{"issue":"22","key":"10.4065\/mcp.2009.0603_bib122","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9594","key":"10.4065\/mcp.2009.0603_bib123","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.4065\/mcp.2009.0603_bib124","first-page":"78","article-title":"Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial [abstract 78]","volume":"110","author":"Waage","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.4065\/mcp.2009.0603_bib125","first-page":"649","article-title":"Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study. [abstract 649]","volume":"112","author":"Wijermans","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"15","key":"10.4065\/mcp.2009.0603_bib126","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2009.0603_bib127","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"key":"10.4065\/mcp.2009.0603_bib128","first-page":"652","article-title":"A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. [abstract 652]","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"28","key":"10.4065\/mcp.2009.0603_bib129","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide Treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.4065\/mcp.2009.0603_bib130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"issue":"12","key":"10.4065\/mcp.2009.0603_bib131","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"19","key":"10.4065\/mcp.2009.0603_bib132","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma [letter]","volume":"354","author":"Rajkumar","year":"2006","journal-title":"N Engl J Med"},{"issue":"19","key":"10.4065\/mcp.2009.0603_bib133","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma [letter]","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.4065\/mcp.2009.0603_bib134","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611602966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611602966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T04:40:50Z","timestamp":1705984850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611602966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":134,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0025619611602966"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2009.0603","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2009.0603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}